The Egyptian Journal of Internal Medicine

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 31  |  Issue : 4  |  Page : 556--562

Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy


Ahmed Al-Khattib1, Adham El-Nakeeb2, Nevine I Musa3, Kerolous B.A. Dous2, Heba Aly1 
1 Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Hepatology and Gastroenterology, Sohag Cardiology and Hepatogastroentrology Center, Faculty of Medicine, Sohag University, Sohag, Egypt
3 Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Heba Aly
MD of Tropical Medicine Ain-Shams University, 39 Elmesery Street Alzeitoun, Cairo, 11213
Egypt

Background Accurate evaluation of the degree of liver fibrosis in patients with chronic liver diseases is crucial to make therapeutic decisions and to determine the prognosis of liver disease and also the protocol of further follow-up. Multiple noninvasive methods have been used successfully in the prediction of fibrosis; however, early changes in noninvasive parameters of hepatic fibrosis after effective antiviral therapy are still not well unknown. The aim of the paper was to evaluate early changes in the hepatic fibrosis-related parameters in patients with chronic hepatitis C virus (HCV) infection using shear wave elastography (pSWE) and serum parameters [aspartate aminotransferase-platelet ratio index (APRI) and fibrosis-4 score (FIB4)] before and 24 weeks after sofosbuvir-based antiviral therapy. Materials and methods This is a prospective cohort study that included 109 Egyptian patients with chronic hepatitis C. pSWE values were recorded as well as APRI and FIB4 scores were calculated at baseline and at 12 and 24 weeks after treatment. Results A total of 109 HCV-infected patients were included, with mean age of 45.76±13.91 years. Overall, 25 (22.90%) patients had cirrhosis and were treated with sofosbuvir 400 mg/day, daclatasvir 60 mg/day, and weight-based ribavirin. Moreover, 84 (77.10%) were treated with sofosbuvir 400 mg/day and daclatasvir 60 mg/day. The overall sustained virological response-12 rate was 100%. There were significant improvements in APRI score (from 0.64±0.66 at baseline to 0.26±0.22 at 24 weeks after treatment) and FIB4 score (from 1.77±1.77 at baseline to 1.11±1.04 at 24 weeks after treatment), with P value of 0.0001 in both. In addition, there was a significant reduction in liver stiffness measurements by pSWE 24 weeks after treatment (from 1.72±0.55 m/s at baseline to 1.48±0.44 m/s at 24 weeks after treatment, with P=0.003). Conclusion Sofosbuvir-based treatment regimens for chronic HCV infection result in significant improvement of the fibrosis scores (FIB4 and APRI) 24 weeks after treatment. Moreover, there was a significant reduction in the liver stiffness measurements by pSWE.


How to cite this article:
Al-Khattib A, El-Nakeeb A, Musa NI, Dous KB, Aly H. Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy.Egypt J Intern Med 2019;31:556-562


How to cite this URL:
Al-Khattib A, El-Nakeeb A, Musa NI, Dous KB, Aly H. Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy. Egypt J Intern Med [serial online] 2019 [cited 2020 Nov 1 ];31:556-562
Available from: http://www.esim.eg.net/article.asp?issn=1110-7782;year=2019;volume=31;issue=4;spage=556;epage=562;aulast=Al-Khattib;type=0